36 results about "Veratric acid" patented technology

The invention discloses a composite of all-trans-retinoic acid and liposome and application thereof. The composite of all-trans-retinoic acid and liposome consists of the liposome and the all-trans-retinoic acid encapsulated in the liposome. The composite is prepared by a method comprising: 1) dissolving lipid materials and the all-trans-retinoic acid to prepare a mixture of a lipid membrane and the all-trans-retinoic acid; 2) hydrating the mixture of the liquid membrane and the all-trans-retinoic acid to prepare a hydration product; and 3) performing ultrasonic on the hydration product to prepare the composite of the all-trans-retinoic acid and the liposome. Experiments of the invention prove that the composite of the all-trans-retinoic acid and the liposome can be used for inhibiting the reproduction of tumor cells, and the combined application of the composite of the all-trans-retinoic acid and the liposome and Vinorelbine invisibile liposome produces the strongest inhibitory effect on the recrudesce of tumors.

The invention discloses an all-trans retinoic acid-camptothecin anticancer drug conjugate as well as a preparation method and application thereof. The structural formula of the all-trans retinoic acid-camptothecin anticancer drug conjugate is shown in a formula (I), (II), (III), (IV), (V) or (VI). The all-trans retinoic acid-camptothecin anticancer drug conjugate has good solubility in Tween, polyoxyethylene castor oil, a Poly(ethylene adipate)-polylactic acid copolymer and a Poly(ethylene adipate)-poly (lactic acid-glycollic acid) copolymer, can be self assembled into nanometer grains in water, can be directly injected or taken orally or processed into other dosage forms. According to the all-trans retinoic acid-camptothecin anticancer drug conjugate disclosed by the invention, as all-trans retinoic acid and SN-38 or camptothecin take synergistic effect, compared with a conjugate only containing one of irinotecan, SN-38 and all-trans retinoic acid, the all-trans retinoic acid-camptothecin anticancer drug conjugate has good tumor suppression effect.

The invention relates to a multi-drug delivery retinoic acid nanoparticle solution and application thereof as a tumor treating medicine. Retinoic acid, a histone deacetylase inhibitor, pirenfox, an emulsifier, a substrate and a cosolvent are used as raw materials, and multi-drug delivery retinoic acid nanoparticles are synthesized by a solvent dilution method through one step. In the formula, as auxiliary materials, the substrate, the emulsifier and the cosolvent play roles in stabilizing the nanoparticles and regulating the particle size; as auxiliary drugs, the histone deacetylase inhibitor and the pirenfox are used for reversing the tolerance of tumor cells to retinoic acid medicines; as a main drug, the retinoic acid induces differentiation and apoptosis of the tumor cell. The components complement one another to play a synergistic role. The multi-drug delivery retinoic acid nanoparticle solution is reasonable in drug collocation, clear in acting mechanism and simple in preparation process, has a passive tumor targeting property, and is expected to be applied to the field of tumor treatment.

The invention discloses application of an oleanolic acid and retinoic acid pharmaceutical composition to medicament for treating insulin resistance and diabetes. Intraperitoneal injection of the oleanolic acid and retinoic acid pharmaceutical composition to diabetic animal can significantly lower the blood glucose level; and addition of the oleanolic acid and retinoic acid pharmaceutical composition in culture solution for culturing liver cells can significantly promote transmission of an insulin signal. Therefore, the oleanolic acid and retinoic acid pharmaceutical composition can be applied to medicaments for treating diabetes, insulin resistance and metabolic syndrome closely related to insulin resistance.

The invention discloses a method for synthesizing veratric acid, which is characterized in that: in a reaction that aldehydes are selectively catalytically oxidized by silver nitrate to generate carboxylic acid, the aldehydes are catalytically oxidized to generate the carboxylic acid under the catalysis of the silver nitrate and the oxidation of hydrogen peroxide. The technical scheme comprises the following steps of: (1) performing the oxidation process: dissolving 3,4-dimethoxybenzaldehyde in acetonitrile, adding a catalyst silver nitrate in an amount which is one tenth weight of the 3,4-dimethoxybenzaldehyde, dripping an oxidant hydrogen peroxide in an amount which is ten times weight of the 3,4-dimethoxybenzaldehyde, reacting at 50 DEG C for 2.1 hours, quenching the reaction by using sodium thiosulfate, and extracting by using dichloromethane; and (2) washing a product obtained in the step (1) by using saturated sodium bicarbonate, adjusting the pH of a water layer to be 5-6 by using hydrochloric acid, extracting by using dichloromethane, vaporizing the solvent to obtain the veratric acid. The hydrogen peroxide is a cheap and readily-available oxidant, and the silver nitrate is taken as the catalyst, so the reaction efficiency is effectively improved.

An N-trans-vitamin A acid ethylamide derivative is prepared through reaction between trans-vitamin A acid powder, phenol and phosphorus trichloride, stirring in nitrogen gas, extracting by ether, chromatography, and mass spectroscopy. It can regulate the fucosyltransferase and suppress liver cancer cell with lower poison, so it can be used to preparing antineoplastics.

The invention belongs to the technical field of biology and particularly relates to a pharmaceutical application of all-trans-retinoic acid.By extensive and deep researches, the new application of the all-trans-retinoic acid to preparation of medicines capable of inducing formation of tissue resident memory T cells is discovered for the first time and lays a foundation for development of brand-new mucosal immunization strategies taking the ATRA (all-trans-retinoic acid) as an adjuvant.

The invention belongs to the field of natural organic chemistry, and particularly relates to a method for enriching and purifying veratric acid in globeflower by using macroporous adsorbent resin. By using macroporous adsorption technology to separate and purify veratric acid, the invention has the characteristics of good adsorption selectivity for veratric acid, high adsorption and desorption speed, high adsorption capacity, abundant material sources, low production cost, obvious separation effect and high extraction purity, can be used for extracting veratric acid conveniently and quickly, can be used to obtain a semi-finished product of which the content of veratric acid is higher than 30% and a final product of which the content of veratric acid is higher than 90%, and can overcome the defects of low extraction yield and low extraction purity in the conventional method. The macroporous adsorbent resin, which has the advantages of stable physicochemical properties, large surface area, high exchange speed, high mechanical strength, high antipollution capability and high thermal stability, is used for selectively adsorbing veratric acid from the solution in a physical adsorption mode; and the invention has the advantages of high adsorption and desorption speed, and high adsorption capacity.

This invention relates to a method for synthesizing organic compound, more specifically, veratric acid. The method comprises: performing disproportionation salification reaction on veratraldehyde with aldehyde and alkali in alcohol/water solvent, and acidifying to obtain veratric acid. The method acoids the utilization of 1, 3-dinitrobenzene and potassium butoxide, and has such advantages as little environmental pollution, high productivity and short production cycle.

The invention relates to a compound all-trans vitamin A acid dispersible paste and the preparation method and application. The all-trans vitamin A acid dispersible paste comprises all-trans vitamin A acid 10-50 units, beclomeasone propionate 10 -50 units, urea 5000-20000 units and base material 80000-95000 units. The method for preparing paste comprises following steps: (1) collecting 50 -65g urea, 150-180g glycerin, 3-5g dodecyl sodium sulfate, 6-10g triethanolamine, adding water into them unti the weight reaches 400-450g, (2) taking 20 -40g glycerel monostearte, 100-120g geoceric acid, 50 -70g white petrolatum, 190-200g liquid paraffin and 1-3g phenethyl ester as oil phase; (3)putting the two phases into container, heating until dissolution, keeping it at 60-80 Deg. C, pouring oil phase into aqueous phase, adding 0. 125-1g all-trans vitamin A acid, 0. 125-1. 5g beclomeasone propionate, stirring. The paste can be coated on cicatrix directly to prevent cicatrix recurrent, reduce cicatrix coloring matter deposition and promote cicatrix recovery.

There is provided a composition including a veratric acid for preventing or treating inflammatory diseases. The veratric acid of the present invention has an excellent effect of inhibiting production of nitric oxide, an excellent activity of inhibiting production of IL-1β as a pro-inflammatory cytokine, and an excellent effect of inhibiting phosphorylation of MAPK, NF-κB, GSK-3β, and c-Raf in a macrophage cell stimulated by a stimulation factor that causes an inflammatory reaction. Thus, it can be used for development of medicines for treating inflammatory diseases which can be caused by excessive inflammatory reactions. Further, the veratric acid of the present invention does not induce toxicity to cells and is stable in the body. Thus, it can be used as a material of a health functional food capable of preventing or improving inflammatory diseases.

The invention relates to a medicinal control release nanometer and method for making same, in particular a retinoic acid release control nanomicrosphere and its preparation method, the constituents of the composition are polylactic acid (PLA), vitamin A acid (RA) and gelatin aqueous solution.

The invention relates to the technical field of chemical production, and provides a synthetic method of methyl 3, 4-dimethoxybenzoate. According to the invention, dicyclohexylcarbodiimide is used as a catalyst to catalyze the esterification reaction of veratric acid and methanol, the reaction conditions are mild, the product yield is high, the methanol consumption is less, and dicyclohexylcarbodiimide has no danger, is green and environment-friendly, and is more suitable for industrial production. Furthermore, in the synthesis method provided by the invention, the dicyclohexylcarbodiimide and the solvent can be recycled, and the amount of generated three wastes is small.

The invention discloses a pharmaceutical composition for removing residual liver cancer stem cells with combined use of arsenic trioxide As2O3 and all-transretinoic acid ATRA; an effective component is arsenic trioxide and all-transretinoic acid according to the final concentration of the total liquid amount. The invention also provides an application of the pharmaceutical composition in preparation of drugs for preventing and treating recurrence and metastasis of liver cancer after resection. The beneficial effects comprise that according to the pharmaceutical composition and the applicationthereof provided by the invention, arsenic trioxide is disclosed to have an effect of inducing differentiation of the liver cancer stem cells, and arsenic trioxide and all-transretinoic acid can inhibit PML proteins; moreover, arsenic trioxide and all-transretinoic acid can regulate down the expression of a key gene Oct4 of the PML downstream liver cancer stem cells respectively. A traditional wayof inducing apoptosis of liver cancer cells is broken through, and aiming at the residual liver cancer stem cells after resection of liver cancer, the differentiation of the liver cancer stem cells is induced by small-dose arsenic trioxide; with the combination of all-transretinoic acid and arsenic trioxide, the pharmaceutical composition can play a synergistic role, reduces the amount of arsenictrioxide and achieves the effect of eliminating the residual liver cancer stem cells.